Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
about
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.The roles of chromatin-remodelers and epigenetic modifiers in kidney cancerCytoplasmic expression of BAP1 as an independent prognostic biomarker for patients with gliomasComprehensive review of BAP1 tumor predisposition syndrome with report of two new casesRecurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.Molecular genetics of clear-cell renal cell carcinomaThe prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.Ambiguous melanocytic tumors with loss of 3p21.Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma.Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesisLoss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.Sunitinib re-challenge in advanced renal-cell carcinoma.P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific deathNew strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival.Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.What advances have been made in immune-therapy for renal cell carcinoma?Progression inference for somatic mutations in cancer.Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens.Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis.Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.Precision medicine from the renal cancer genome.Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features.Lack of TMEM27 expression is associated with postoperative progression of clinically localized conventional renal cell carcinoma.High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma.A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
P2860
Q27853165-4C3B6FCE-5D7E-43E5-8DB2-8C97AE0ED128Q28083152-AA5CD9DD-6532-4E7A-B126-2332D66F29F2Q28383444-5130E477-CB41-4472-8039-0F8CAB109CF4Q28397229-E1655F90-4C42-43D8-8139-66A5A50A4373Q31163345-30190CD9-0707-43C4-9773-B1EF70BDC586Q33729097-901E5FE0-1840-40B8-B6AB-3C84AF15CA18Q33842185-F408C0F5-13FF-4800-8D40-0BF46FF549C8Q33911349-A43D3D40-01B8-4A35-862B-D91D7809085BQ33913967-D34BB42F-478C-4BA6-BCE1-E195EEF02CBDQ34580977-FF43B24D-8BCE-4BE5-B657-D950C56074B1Q34758616-2E981E7A-ECFB-475C-AC20-EB059AA06E1DQ34917972-0ED950FD-1D67-4BC4-9EA6-F2B5FB2F2E6AQ35451764-A811DDA0-6ADF-4C4D-955A-2C882F7860F0Q35678358-3FA5FC0C-EA2E-4BE9-A4D9-4733F03D63B6Q36092896-296B1472-7740-4B8D-9A3A-88C41F7992F2Q36169098-D9BA10E0-8513-43B7-BF0E-05D1585016F2Q36261661-1DD87658-2484-481D-AFFE-6A8AD3948BB0Q36317488-0A623555-C59F-4296-8236-6FE2DB54689DQ36420712-57450384-7BD3-42BD-AE1C-3C0FE627E630Q36696610-24C1DC56-FF39-48D4-9E1C-CD801768533EQ37016755-72089CB4-2A56-46E0-8654-7046A292D739Q37172780-1E860C32-9FFB-4612-B518-EDAF91D1DF99Q37573538-0925BD71-4B42-4A14-AAE6-48CABC8C4941Q38545726-791D7291-FFB3-4329-A970-BC0AC8DAC5A4Q38617242-945E07EC-4F4D-446D-A9DB-46CDF1535921Q38759282-2BCD6AE2-6A84-40A6-B532-2A7048E993D1Q38793244-C5D6E335-54DE-475C-BD0D-1DE52AC48352Q38794945-914FB73C-0EA8-4217-BD83-BC444A7E113BQ38810854-F2614A44-873C-4C98-8356-88A7C3CDD9CCQ38843978-C742C1E7-1D13-422A-AA96-909ABEB9A25BQ38861806-2A8E2A44-CE46-4044-95DB-9D24B33E2FDFQ38910995-7DCB916F-5081-44C7-952E-C904A9C19919Q38970282-DC047367-2935-4953-B978-2F0366F85A0FQ40028818-5F5B4C26-A141-4A21-A87E-C0742A2936CCQ40650893-7CAC39DC-74C3-4E76-804A-2920F855A2D9Q41221347-B9996409-AB64-46AE-A2B0-5F99C0C48A8AQ41242139-8ED7CE51-5938-493A-B2B0-E7C2AEF4078EQ42728294-CE02B2A9-5A9C-4228-A7D0-FFCC0FF4F9D0Q46773554-AEA45DC2-7ACA-4C19-B817-30EF5D370D3CQ47252459-6C4253AF-8BB2-4AF6-99A4-03186F87ACE7
P2860
Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.
@ast
Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.
@en
type
label
Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.
@ast
Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.
@en
prefLabel
Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.
@ast
Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.
@en
P2093
Alexander Parker
Daniel J Serie
Dinesh Rakheja
Eugene Frenkel
James Brugarolas
Jeanette E Eckel-Passow
John C Cheville
Mansi Parasramka
Payal Kapur
P2860
P304
P356
10.1002/CNCR.28521
P407
P577
2013-12-30T00:00:00Z